RxDoctor Payments Data

Derrick Tooth, MD

Urology · Manchester, MENPI 1639260847

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $612 of the $685 with a category attached, or 89.3%. 11 manufacturers reported payments, led by Dentsply IH AB at 26.7% of the total. Reporting peaked in 2023 at $240 and has fallen 75.8% since, to $58 in 2025. That places this record below the midpoint for urology clinicians in ME, where the typical reported total is $1,024.

$685in general payments, 2019–2025

Across 29 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dentsply IH AB$183
  • Pfizer$130
  • Progenics Pharmaceuticals, Inc.$87
  • Urogen Pharma, Inc.$81
  • AbbVie$55
  • Boston Scientific$40
  • plus $109 from 5 others

What the payments were for

  • Food & beverage$61289%
  • Education$7311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$685 in reported general payments places this provider in the 40th percentile of 59 urology providers in Maine.

See all urology providers in Maine

Medicare billing

Part B allowed, 2024
$60,965
Medicare patients
320
Services billed
611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron57$39,301
GemtesaVibegron13$18,282
Tamsulosin Hcl292$3,360
Finasteride129$1,403
Cefpodoxime Proxetil17$512
Bicalutamide20$397
Ciprofloxacin Hcl43$92
Sildenafil Citrate12$75
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim15$44
Levofloxacin20$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$24$18,28213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 59 urology providers in Maine.

Other urology in Manchester

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →